Prosecution Insights
Last updated: November 20, 2026
Application No. 18/694,894

In Silico Generation of Binding Agents

Non-Final OA §102§103
Filed
Mar 22, 2024
Priority
Sep 24, 2021 — provisional 63/261,646 +1 more
Examiner
KASENGE, CHARLES R
Art Unit
2116
Tech Center
2100 — Computer Architecture & Software
Assignee
Flagship Pioneering Inc.
OA Round
1 (Non-Final)
84%
Grant Probability
Favorable
1-2
OA Rounds
2m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allowance Rate
1114 granted / 1327 resolved
+28.9% vs TC avg
Moderate +14% lift
Without
With
+13.8%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
33 currently pending
Career history
1379
Total Applications
across all art units

Statute-Specific Performance

§101
8.5%
-31.5% vs TC avg
§103
30.4%
-9.6% vs TC avg
§102
41.2%
+1.2% vs TC avg
§112
13.1%
-26.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1327 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-9, 11-15, 19-29, 31, 35-39, 41 and 43-47 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Feinberg et al. U.S. PGPub 2019/0272468 (hereinafter “Feinberg”). Regarding claims 1 and 46, Feinberg discloses a method comprising providing one or more associated biopolymer sequences (e.g. proteins) to conform to a reference structure, the reference structure comprising a target complex (e.g. ¶44, 88 and 93), the associated biopolymer sequences obtainable by a method comprising: embedding a graph representation (e.g. graph) using a neural network, the graph representation featurized from the reference structure and comprising a topology of a biopolymer (e.g. protein) with monomers as nodes and interactions between monomers (e.g. atom) as edges (e.g. ¶44-46, 54-55, 64 and 85-88); processing the graph representation with a graph neural network or equivariant neural network that iteratively updates node and edge embeddings with a learned parametric function (e.g. ¶44-46, 54-55, 64 and 85-88); converting the embedded graph representation to an energy landscape using a decoder (e.g. ¶23-26 and 139-142); and obtaining one or more associated biopolymer sequences (e.g. set of conformations of the set of molecules) from the energy landscape (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 2, Feinberg discloses the method of claim 1, wherein the energy landscape is a conditional generative model for sequences (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 3, Feinberg discloses the method of claim 1, wherein the energy landscape is a conditional random field representing the target complex and the one or more associated biopolymer sequences (e.g. ¶81 and 145). Regarding claim 4, Feinberg discloses the method of claim 1, wherein obtaining the one or more associated biopolymer sequences from the energy landscape employs a maximum likelihood method (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 5, Feinberg discloses the method of claim 1, wherein obtaining the one or more associated biopolymer sequences from the energy landscape employs an energy minimization process (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 6, Feinberg discloses the method of claim 5, wherein the energy minimization process employs a Monte Carlo simulation, simulated annealing, integer-linear programming, genetic process, variational inference, or continuous relaxation based optimization (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 7, Feinberg discloses the method of claim 1, wherein the decoder is a generative model or a conditional generative model selected from at least one of the following: a site-independent model predicting marginal probability of each possible monomer at each position, a conditional random field layer, or Potts model, with pairwise couplings between monomers (e.g. ¶81 and 145), an energy-based model with at least one of higher order interactions and a neural network parameterization, an autoregressively factorized language model, a continuous latent variable model, a discrete latent variable model, and an implicit generative model (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 8, Feinberg discloses the method of claim 1, wherein the decoder is structured as a conditional random field (e.g. ¶81 and 145). Regarding claim 9, Feinberg discloses the method of claim 8, wherein the conditional random field is parameterized by a first term and a second term, the first term representing a monomer bias at each position in the reference structure and the second term representing interdependencies between monomers in the reference structure (e.g. ¶81 and 145). Regarding claim 11, Feinberg discloses the method of claim 1, wherein the target complex comprises the biopolymer (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 12, Feinberg discloses the method of claim 1, wherein the target complex comprises a molecule that is not a biopolymer (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 13, Feinberg discloses the method of claim 1, wherein the target complex is a complex comprising two or more reference biopolymer sequences (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 14, Feinberg discloses the method of claim 13, wherein obtaining the one or more associated biopolymer sequences from the energy landscape further includes obtaining a given associated biopolymer sequences relating to binding the target complex comprising the two or more reference biopolymer sequences (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 15, Feinberg discloses the method of claim 1, wherein the topology comprises a representation of one or more of bond lengths, bond angles, dihedral angles, scalar lengths and angles as vectorial values through radial basis functions, angular embeddings, and at least one categorical discretization (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 19, Feinberg discloses the method of claim 1, wherein the edges comprise one or more of: primary sequence distance between monomers, wherein pairs of monomers are in a same or different polymers in the reference structure, interatomic distances between monomers, relative orientations of atoms at a first monomer i and atoms at a second monomer j, and raw Cartesian displacements between atoms at the first monomer i and the second monomer j (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 20, Feinberg discloses the method of claim 1, further comprising: providing a full chain design for the one or more associated biopolymer sequences to conform to the reference structure, the reference structure including at least one of a structure formed by naturally occurring sequences, structures formed by an in silico generated sequence, and structures generated in silico unassociated with a sequence (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 21, Feinberg discloses the method of claim 1, further comprising: providing a design of interfacial monomers of the one or more associated biopolymer sequences to conform to the reference structure (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 22, Feinberg discloses the method of claim 1, further comprising: providing a design of surface monomers of the one or more associated biopolymer sequences to conform to the reference structure (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 23, Feinberg discloses the method of claim 1, further comprising: providing the one or more associated biopolymer sequences to conform to the reference structure using a limited set of monomers (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 24, Feinberg discloses the method of claim 1, wherein the reference structure comprises a backbone of the biopolymer (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 25, Feinberg discloses the method of claim 24, wherein the backbone omits at least one side chain of the biopolymer (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 26, Feinberg discloses the method of claim 1, further comprising: concurrently or sequentially altering the one or more associated biopolymer sequences to modulate one or more biophysical properties or pharmacodynamic properties of the one or more associated biopolymer sequences, the one or more biophysical properties or pharmacodynamic properties selected from: isoelectric point, weight, hydrophobicity, melting temperature, stability, K.sub.on, K.sub.off, or K.sub.d, half-life, enzymatic function, aggregation, and functional activity (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 27, Feinberg discloses the method of claim 1, wherein the one or more associated biopolymer sequences is a polypeptide (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 28, Feinberg discloses the method of claim 27, wherein the polypeptide comprises one or more non-canonical amino acids (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 29, Feinberg discloses the method of claim 27, wherein the polypeptide comprises one or more D-amino acids (e.g. ¶131 and 134). Regarding claim 31, Feinberg discloses the method of claim 27, wherein the polypeptide is a ligand or receptor, and the reference structure is a ligand-receptor complex (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 35, Feinberg discloses the method of claim 1, further comprising: training on the target complex, wherein the target complex involves multiple chains (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 36, Feinberg discloses the method of claim 1, wherein the one or more associated biopolymer sequences are proteins and the energy landscape is a conditional random field (e.g. ¶81 and 145). Regarding claim 37, Feinberg discloses the method of claim 1, wherein the edges are initialized using edge features based on geometric and structural relationships between the biopolymer (e.g. ¶44-46, 54-55, 64 and 85-88). Regarding claim 38, Feinberg discloses a method comprising providing one or more associated biopolymer sequences to conform to a reference structure, the reference structure comprising a target complex (e.g. ¶44, 88 and 93), the associated biopolymer sequences obtainable by a method comprising: obtaining a first biopolymer sequence from an energy landscape, the energy landscape generated based on a graph representation embedded using a neural network, the graph representation featurized from the reference structure and comprising a topology of biopolymer sequences as nodes and interactions between monomers as edges (e.g. ¶44-46, 54-55, 64 and 85-88); and generating one or more additional biopolymer sequences using the energy landscape, free of using the graph representation (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 39, Feinberg discloses the method of claim 38, further comprising synthesizing the one or more additional biopolymer sequences (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 41, Feinberg discloses the method of claim 38, further comprising producing one or more of the additional biopolymer sequences (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 43, Feinberg discloses the method of claim 38, further comprising administering to a subject in need a particular biopolymer sequence, the particular biopolymer sequence being a given biopolymer sequence from amongst the first biopolymer sequence obtained and the one or more additional biopolymer sequences generated (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153). Regarding claim 47, Feinberg discloses the biopolymer sequence of claim 46, wherein the biopolymer sequence is at least one of: a polypeptide (e.g. ¶44-46, 54-55, 64 and 85-88) and an antibody. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 16 is/are rejected under 35 U.S.C. 103 as being unpatentable over Feinberg as applied to claims above, and further in view of Steemers et al. U.S. PGPub 2021/0102194 (hereinafter “Steemers”). Regarding claim 16, Feinberg does not explicitly disclose the topology being based on k-nearest neighbors. Steemers discloses a topology based on k-nearest neighbors, wherein k is about: 10, 15, 20, 25, 30, 35, 40, 45, or 50 (e.g. ¶487 and 499). At the time the invention was filed, it would have been obvious to a person of ordinary skill in the art to use k-nearest neighbor approach to model a topology. One of ordinary skill in the art would have been motivated to do this since it is a way to analyze data and produce a graph. Therefore, it would have been obvious to modify Feinberg with Steemers to obtain the invention as specified in claim 16. Claim(s) 40 and 42 is/are rejected under 35 U.S.C. 103 as being unpatentable over Feinberg as applied to claims above, and further in view of Wei et al. U.S. PGPub 2021/0027862 (hereinafter “Wei”). Regarding claim 40, Feinberg discloses a method further comprising contacting the one or more additional biopolymer sequences with an analyte (e.g. ¶27, 81, 91, 110, 117, 131, 145-146, 150 and 153), but does not explicitly disclose the analyte is a biological fluid. Regarding claim 42, Feinberg does not disclose a method wherein the produced one or more of the additional biopolymer sequences is an antibody. Wei discloses analyte being a biological fluid (e.g. ¶239). Wei discloses additional biopolymer sequences being an antibody (e.g. ¶112). At the time the invention was filed, it would have been obvious to a person of ordinary skill in the art to produce antibodies with biological fluid. One of ordinary skill in the art would have been motivated to do this since antibodies have desirable the properties of fighting pathogens or toxins. Therefore, it would have been obvious to modify Feinberg with Wei to obtain the invention as specified in claims 40 and 42. Allowable Subject Matter Claims 10, 17, 18, 30 and 32-34 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The following is an examiner’s statement of reasons for allowance: Regarding claim 10, the prior art of record does not disclose a method, wherein the one or more associated biopolymer sequence is a protein and the conditional random field is characterized by the formula wherein s refers to monomer identity at position i, X refers to an entire backbone structure of the reference structure, h.sub.i[s.sub.i; X] refers to a bias term for monomer type s.sub.i at position i that is output by the network given X, and J.sub.ij[s.sub.i,s.sub.j; X] refers to a coupling term between monomer type s.sub.i at position i and monomer type s.sub.j at position j. Regarding claim 17, the prior art of record does not disclose a method, wherein the topology is based on monomer centroid distance of about: 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 angstroms. Regarding claim 30, the prior art of record does not disclose a method wherein the polypeptide is an antibody or antigen-binding fragment thereof, and the reference structure is an antibody-antigen complex. Regarding claim 32, the prior art of record does not disclose a wherein the polypeptide is an enzyme or substrate, and the reference structure is an enzyme-substrate complex. Regarding claim 33, the prior art of record does not disclose a wherein the method can provide one or more n-mer biopolymer sequences in under 3 seconds, wherein n is greater than 500. Regarding claim 34, the prior art of record does not disclose a wherein the one or more associated biopolymer sequences is a protein and wherein the model neural network was trained: using an ensemble of 1000, 2000, 3000, 5000, 10000, 50000, 100000, 500000, or 1000000 more protein structures, e.g., some (e.g., 10, 20, 30, 40, 50, 60, 70, 80, 90, 95%) or substantially all of the structures from the Protein Data Bank (PDB). Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARLES R KASENGE whose telephone number is (571)272-3743. The examiner can normally be reached Monday - Friday 7:30am to 4pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Kenneth Lo can be reached at (571) 272-9774. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. CK October 16, 2026 /CHARLES R KASENGE/Primary Examiner, Art Unit 2116
Read full office action

Prosecution Timeline

Mar 22, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12801117
METHOD FOR OPERATING AN ADDITIVE MANUFACTURING DEVICE
4y 4m to grant Granted Nov 17, 2026
Patent 12803288
INFORMATION PROCESSING METHOD, INFORMATION PROCESSING APPARATUS, AND NON-TRANSITORY COMPUTER READABLE MEDIUM
2y 6m to grant Granted Nov 17, 2026
Patent 12793533
METHOD AND DEVICE FOR MINING ALARM CAUSALITY, AND STORAGE MEDIUM
2y 8m to grant Granted Nov 10, 2026
Patent 12782927
Manufacture Modeling And Monitoring
3y 10m to grant Granted Nov 03, 2026
Patent 12769262
ENERGY STORAGE SYSTEM CONTROL
3y 10m to grant Granted Oct 20, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
84%
Grant Probability
98%
With Interview (+13.8%)
2y 10m (~2m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1327 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month